121 related articles for article (PubMed ID: 19028616)
1. The Renaissance of platinum-based chemotherapy for metastatic breast cancer.
Meriggi F; Di Biasi B; Zaniboni A
J Chemother; 2008 Oct; 20(5):551-60. PubMed ID: 19028616
[TBL] [Abstract][Full Text] [Related]
2. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based compounds for the treatment of metastatic breast cancer.
Shamseddine AI; Farhat FS
Chemotherapy; 2011; 57(6):468-87. PubMed ID: 22248721
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer: review of platinum-based cooperative group trials.
Pegram M
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S2-9. PubMed ID: 19780241
[TBL] [Abstract][Full Text] [Related]
5. [Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].
Lopez M; Di Lauro L; Viola G; Conti F; Foggi P; Vici P
Clin Ter; 2009; 160(6):489-97. PubMed ID: 20198293
[TBL] [Abstract][Full Text] [Related]
6. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
Belani CP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):25-33. PubMed ID: 15726531
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
8. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
Awada A
Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
[TBL] [Abstract][Full Text] [Related]
9. Current and planned clinical trials with trastuzumab (Herceptin).
Baselga J
Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
11. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
12. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
Rivera E
Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone: clinical role in metastatic breast cancer.
Denduluri N; Swain S
Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
[TBL] [Abstract][Full Text] [Related]
14. Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands.
van Herk-Sukel MP; van de Poll-Franse LV; Creemers GJ; Lemmens VE; van der Linden PD; Herings RM; Coebergh JW; Voogd AC
Breast J; 2013; 19(4):394-401. PubMed ID: 23663128
[TBL] [Abstract][Full Text] [Related]
15. Management of endocrine resistant breast cancer.
Sundar S; Decatris MP; O'Byrne KJ
J Br Menopause Soc; 2004 Mar; 10(1):16-23. PubMed ID: 15107207
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic breast cancer: looking towards the future.
Amar S; Roy V; Perez EA
Breast Cancer Res Treat; 2009 Apr; 114(3):413-22. PubMed ID: 18465221
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
18. [Current trends in pharmacotherapy of breast cancer].
Boér K
Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
[TBL] [Abstract][Full Text] [Related]
19. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
20. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
